8 oktober 2022
A Side-By-Side Comparison of Antibiotics V Native Phage Therapy for Lyme Disease; Bron https://www.facebook.com/BiologixCenter/ en Bron https://biologixcenter.com/inpt-phage-t ... e-disease/
PhagenCorp; Bron https://phagencorp.com/..100% elimination of infection in 92% of people studied, verified by independent third-party laboratory testing..
..The ultimate indication of phage activation is the independent phage lab testing, which shows high phage titers prior to treatment and after treatment. With no bacteria left, their phages also die, resulting in a zero-phage titer..
..Lastly, no other form of medicine, natural, pharmaceutical, or energy medicine has ever been documented with such comprehensive and sensitive independent lab testing to be able to eliminate the entire targeted bacterial population so rapidly and completely. The only known mechanism in the body ever documented in any laboratory, anywhere in the world to be able to eliminate the target infection this rapidly and completely, is the action of lytic bacteriophages. This is not a manipulation of the science to fit our views, it is a fact..
De 'klinische en wetenschappelijke' bevindingen van de 'Induced Native Phage Therapy for the Treatment of Lyme Disease and Relapsing Fever' zijn gebaseerd op de uitslagen van de experimentele en niet-gevalideerde 'Phelix Phage Borrelia test'? Met de test kan géén diagnose Borrelia burgdorferi sensu lato (s.l) en of B. miyamotoi/Relapsing Fever worden gesteld.Announcement
In December of 2021, we were excited to present our strong, peer-reviewed, retrospective, proof of concept research of Inducen-LD/RF to the world. In this publication, we demonstrated the apparent rapid elimination of Borrelia strains, using the latest and most sensitive lab testing, coinciding with significant clinical improvements in many participants suffering with previously treatment-resistant Borrelia infections.
To ensure absolute credibility of our innovation, and the industry as a whole, we feel that the completion of the double-blinded, independent research study, and the ongoing independent product research taking place both in the U.S. and Europe, is necessary before the product is released to healthcare practitioners. We apologize for the delay, however our goal is to ensure the highest integrity of the science, and the accuracy of or subsequent modifications of the concepts and representations...It is expected that PhagenCorp will be making the Inducen formulas available to healthcare professionals within the next four months..
Publicatie 29 november 2021
Original article A Retrospective Review - 'Induced Native Phage Therapy for the Treatment of Lyme Disease and Relapsing Fever: A Retrospective Review of First 14 Months in One Clinic' by David A. Jernigan , Martin C. Hart, Keeley K. Dodd, Samuel Jameson, Todd Farney; Bron https://www.cureus.com/articles/76183-i ... one-clinic
With the advent of the Phelix Borrelia-phage (PBP) testing, we can now determine the presence or absence of Borrelia infection with a much higher degree of certainty..
..Phelix Borrelia-phage testing
No published normative data existed for the use of INPT in patients with LD or RF in that it is an emerging technology; however, prior peer-reviewed technologies support the premise . The clinical advancements of the technologies leading up to the development of INPT took place over the course of 26 years, the effects of which were largely restricted to clinical observation and adjunctive BES testing incorporated into the standard programs of care, until the introduction of the newly released laboratory test, PBP qPCR . High-sensitivity of >90% and 100% specificity, showing no false positives and few false negatives, combined with the speed of verification of treatment effect being only four days post-bacterial clearance, made the PBP testing ideal for detection of early or late LD/RF.
Conventional antibody testing, such as Lyme Western blot testing would not be of use because antibodies remain circulating in the body for years after the infection is gone, and the testing presents a lack of sensitivity, especially in late-stage illness . The limitations of immunoglobulin M/immunoglobulin G antibody testing and the need for more sensitive testing for Borrelia species are well documented . Discussions of any current assay being able to determine an active or inactive infection are not relevant to this review. More important to this review is the apparent frank presence or absence of the infection as indicated by the presence or absence of the bacteria’s native phages. This criterion is achieved only by the PBP test.
The PBP test undergoes quadruplicate real-time polymerase chain reaction (PCR) tests for three different targets (B. burgdorferi sl, B. miyamotoi, and RF group) for a total of 12 assessments. All positive-like samples are submitted to confirmatory sequencing to rule out false-positive results. The Phelix Phage test (patent no. WO2018083491A1) is performed on whole blood from two ethylenediaminetetraacetic acid (EDTA) tubes. The very first step consists of extracting the DNA using a specific manual method to ensure the best possible recovery of the pathogenic DNA. The extracted DNA undergoes three different qPCRs using proprietary primers and probes for phage-specific detection. The three qPCRs aim to detect the following targets (i) Borrelia miyamotoi, (ii) Borrelia burgdorferi sensu lato (B. burgdorferi ss, B. bissettii, B. bavariensis, B. valaisiana, B. afzelii, and B. garinii), and (iii) RF (B. hermsii, B. recurrentis, B. crocidurae, B. duttonii). Each target is tested in a quadruplicate. The amplified fragments are then analyzed by sequencing to confirm the positivity of the sample (i.e., to rule out false positives)..
The PBP qPCR test was utilized as our standard due to its very high sensitivity to detecting the presence of infection and the immediate evidence of the absence of infection post-treatment. As presented by Louis Teulieres, MD, at the 2019 International Lyme and Associated Diseases Society conference, the PBP testing is statistically the most accurate test..
Frontiers in Microbiology
Publicatie 13 december 2021
Opinion: 'Methodological Shortcomings in the Study on a Prophage-based PCR Test for Lyme Borreliosis' by Freek R. van de Schoor, M. E. Baarsma, Mariska M. G. Leeflang, Volker Fingerle, Gabriele Margos, Joppe W. Hovius and Alje P. van Dam; Bron https://www.frontiersin.org/articles/10 ... 02131/full en Bron viewtopic.php?f=5&t=2322&start=750#p27953
Frontiers in Microbiology
Publicatie 15 maart 2021
Study - 'Targeting multicopy prophage genes for the increased detection of Borrelia burgdorferi sensu lato (s.l.), the causative agents of Lyme disease, in blood' by Jinyu Shan, Ying Jia, Faizal Patel, Louis Teulières and Martha R. Clokie; Bron https://www.frontiersin.org/articles/10 ... 7/abstract
De onderzoeken door de onderzoekscommissies van het European Patent Office (EPO) en het WIPO (World Intellectual Property Organization) gaan interessant worden. Als ook de onderzoeken door de onderzoekscommissies van de African Intellectual Property Organization (OAPI), de African Regional Intellectual Property Organization (ARIPO) en de Eurasian Patent Organization (EAPO).
Stand van zaken European Patent Office (EPO) - WO2022072615 (EP21876463) 'Method of manipulating phages within the body to attack infectious target cells'; Bron https://register.epo.org/application?number=EP21876463
In Europa is in veel landen het patent(octrooi) 'EP3535412 (WO2018083491A1) - 'Phage-based detecition of Borreliosis and means therfor'; (inventors Clokie, Shan en Teulières 'Phelix Phage Borrelia test'); Bron https://register.epo.org/application?nu ... n&tab=main komen te vervallen (in 2021 en 2022).
'Lapse of the patent in a contracting state' - Event history; Bron https://register.epo.org/application?nu ... &tab=event
Bij enkel de landen België; Bron https://bpp.economie.fgov.be/fo-eregist ... ?locale=en Frankrijk; Bron https://data.inpi.fr/brevets/EP3535412 Engeland; Bron https://www.ipo.gov.uk/p-ipsum/Case/App ... 17795037.5 is het patent(octrooi) niet vervallen.
Stand van zaken WIPO (World Intellectual Property Organization); Bron https://www.wipo.int/portal/en/
WO2022072615 - 'Method of manipulating phages within the body to attack infectious target cells' (inventor Jernigan); Bron https://patentscope.wipo.int/search/en/ ... GK-50238-1
Juridische status: in behandeling. Description en Claims; Bron viewtopic.php?f=38&t=2435&start=160#p28831
..The INPT treatment has been shown, by laboratory testing to apparently completely eradicate bacteria, in a retrospective study of INPT treatment of people with qPCR Borrelia-Phage testing confirmed Borrelia, Borrelia-persistor cells, and different strains of Borrelia sp., typically in less than seven days. INPT induced phages can also penetrate bacterial biofilms to reach hidden target bacteria within the subject..